Kuhnl, A;
Roddie, C;
Kirkwood, AA;
Chaganti, S;
Norman, J;
Lugthart, S;
Osborne, W;
... Mikhaeel, NG; + view all
(2024)
Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.
British Journal of Haematology
, 205
(2)
pp. 483-494.
10.1111/bjh.19453.
![[thumbnail of Kirkwood_Kuhnl_BJH RT bridging revision_clean 07.03.24.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Kirkwood_Kuhnl_BJH RT bridging revision_clean 07.03.24.pdf Access restricted to UCL open access staff until 10 April 2025. Download (795kB) |
Abstract
Radiotherapy (RT) has potential synergistic effects with chimeric antigen receptor (CAR) T but is not widely used as bridging therapy due to logistical challenges and lack of standardised protocols. We analysed RT bridging in a multicentre national cohort of large B-cell lymphoma patients approved for 3L axicabtagene ciloleucel or tisagenlecleucel across 12 UK centres. Of 763 approved patients, 722 were leukapheresed, 717 had data available on bridging therapy. 169/717 (24%) received RT bridging, 129 as single modality and 40 as combined modality treatment (CMT). Of 169 patients, 65.7% had advanced stage, 36.9% bulky disease, 86.5% elevated LDH, 41.7% international prognostic index (IPI) ≥3 and 15.2% double/triple hit at the time of approval. Use of RT bridging varied from 11% to 32% between centres and increased over time. Vein-to-vein time and infusion rate did not differ between bridging modalities. RT-bridged patients had favourable outcomes with 1-year progression-free survival (PFS) of 56% for single modality and 47% for CMT (1-year PFS 43% for systemic bridging). This is the largest cohort of LBCL patients receiving RT bridging prior to CAR T reported to date. Our results show that RT bridging can be safely and effectively used even in advanced stage and high-risk disease, with low dropout rates and excellent outcomes.
Archive Staff Only
 |
View Item |
